Atypical Parkinsonism is a class of neurological disorders that mimic Parkinson’s disease (PD), the most common form of parkinsonism, but have another underlying cause. Common symptoms are quite similar to PD, including tremors, stiffness, and slowness of movement. However, other telltale signs may also present, such as difficulty with balance, cognitive impairment, and changes in behavior. The various types of atypical parkinsonism include multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and Lewy body dementia (LBD). Each of these diseases has a unique set of neurological symptoms and progression. MSA is characterized by an inability to move due to lack of coordination, as well as orthostatic hypotension and urinary incontinence. PSP is rarely reversible, resulting in lateralized movement issues, falling, erratic postures, and impaired vision. Similarly, CBD involves rigid postures, slow movements, and impaired cognition. Lastly, LBD is marked by hallucinations, mental confusion, sleep problems, and loss of facial expression. Diagnosis of atypical parkinsonism is complicated because the various types share common symptoms. To differentiate between them, doctors typically rely on a comprehensive evaluation and medical tests like brain MRI and biological testing. Unfortunately, there are no cures for atypical parkinsonism. While medications might help to reduce symptoms or slow the disease’s progression, the best treatment strategies are geared towards maintaining good quality of life. Occupational and physical therapy, Parkinson’s support groups, and lifestyle modifications can help to minimize symptoms and boost overall wellbeing. Social support is also key for managing the emotional toll of an atypical parkinsonism diagnosis.
Title : Novel important cellular responses, signaling mechanisms and therapeutic options in vascular dementia
Yong Xiao Wang, Albany Medical College, United States
Title : TBI updates in 2025
Jonathan Eskenazi, Cedars Sinai / UCLA, United States
Title : A case of vile vindictive primary CNS vasculitis
George Diaz, Memorial Healthcare Systems, United States
Title : Non-pharmacological strategies to counteract oxaliplatin toxicity: Protective effects of vagal nerve stimulation and resistance training on neuropathy, motor dysfunction, and muscle atrophy
Ricardo Aparecido Baptista Nucci, Hospital Sirio-Libanes, Brazil
Title : Synapticare: Integrating sleep data and tau biomarkers to assess depression severity
Medha Menon, John Foster Dulles HS, United States
Title : How have we eliminated infection: From the bone to brain?
Thomas J Webster, Interstellar Therapeutics, United States